文献速递脊柱关节炎

接受乌司奴单抗或肿瘤坏死因子抑制剂治疗的银屑病关节炎患者的性别差异:真实世界数据

Gender-specific differences in patients with psoriatic arthritis receiving ustekinumab or tumour necrosis factor inhibitor: real-world data.
PubMed 文献 · Rheumatology (Oxford) · 2023-01-01

PsABio 是一项非干预性欧洲研究,纳入开始使用生物改善病情抗风湿药(bDMARD;乌司奴单抗或 TNF 抑制剂)的银屑病关节炎(PsA)患者,本事后分析比较男女性患者在基线及治疗 6、12 个月时的药物持续使用、疾病活动度、患者报告结局和安全性。结果显示女性基线疾病更重、12 个月达标比例更低、治疗持续率更低,作者认为更好理解这些差异的机制可能改善女性 PsA 患者的治疗管理。

要点

  • 女性基线 cDAPSA 32.3(95%CI 30.3, 34.2)vs 男性 26.8(24.8, 28.9),女性疾病活动度更高。
  • 12 个月 cDAPSA 低疾病活动度:女性 175/303(57.8%)vs 男性 212/264(80.3%)。
  • 治疗持续率女性低于男性(P ≤ 0.001),缺乏疗效是男女及两种 bDMARD 停药的主要原因。

核心结论

  • 开始 bDMARD 前女性疾病较男性更重,达到有利疾病状态的比例更低,12 个月后治疗持续率更低。
  • 作者认为更好理解这些差异的机制可能改善女性 PsA 患者的治疗管理。

研究设计与样本

  • PsABio 是一项非干预性欧洲研究,纳入开始使用 bDMARD(乌司奴单抗或 TNF 抑制剂)的 PsA 患者。
  • 本分析为事后分析,比较男女性患者基线及治疗 6、12 个月时的药物持续使用、疾病活动度、患者报告结局和安全性。
  • 基线共 512 例女性与 417 例男性,女性与男性病程分别为 6.7 年与 6.9 年。

主要发现

  • 基线女性 vs 男性:cDAPSA 32.3(95%CI 30.3, 34.2)vs 26.8(24.8, 28.9);HAQ-DI 1.3(1.2, 1.4)vs 0.93(0.86, 0.99);PsAID-12 总分 6.0(5.8, 6.2)vs 5.1(4.9, 5.3)。
  • 女性评分改善幅度小于男性。
  • 12 个月 cDAPSA 低疾病活动度:女性 175/303(57.8%)vs 男性 212/264(80.3%);MDA:女性 96/285(33.7%)vs 男性 137/247(55.5%)。
  • 12 个月 HAQ-DI:女性 0.85(0.77, 0.92)vs 男性 0.50(0.43, 0.56);PsAID-12:女性 3.5(3.3, 3.8)vs 男性 2.4(2.2, 2.6)。
  • 治疗持续率女性低于男性(P ≤ 0.001);缺乏疗效是停药的主要原因,与性别及 bDMARD 种类无关。

关键数值与推荐

  • 12 个月 cDAPSA 低疾病活动度:女性 175/303(57.8%)vs 男性 212/264(80.3%)。
  • 12 个月 MDA:女性 96/285(33.7%)vs 男性 137/247(55.5%)。
  • 治疗持续率女性低于男性,P ≤ 0.001。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Investigate effects of gender on disease characteristics and treatment impact in patients with PsA. METHODS: PsABio is a non-interventional European study in patients with PsA starting a biological DMARD [bDMARD; ustekinumab or TNF inhibitor (TNFi)]. This post-hoc analysis compared persistence, disease activity, patient-reported outcomes and safety between male and female patients at baseline and 6 and 12 months of treatment. RESULTS: At baseline, disease duration was 6.7 and 6.9 years for 512 females and 417 males respectively. Mean (95% CI) scores for females vs males were: clinical Disease Activity Index for Psoriatic Arthritis (cDAPSA), 32.3 (30.3, 34.2) vs 26.8 (24.8, 28.9); HAQ-Disability Index (HAQ-DI), 1.3 (1.2, 1.4) vs 0.93 (0.86, 0.99); total PsA Impact of Disease-12 (PsAID-12) score, 6.0 (5.8, 6.2) vs 5.1 (4.9, 5.3), respectively. Improvements in scores were smaller in female than male patients. At 12 months, 175/303 (57.8%) female and 212/264 (80.3%) male patients achieved cDAPSA low disease activity, 96/285 (33.7%) and 137/247 (55.5%), achieved minimal disease activity (MDA), respectively. HAQ-DI scores were 0.85 (0.77, 0.92) vs 0.50 (0.43, 0.56), PsAID-12 scores 3.5 (3.3, 3.8) vs 2.4 (2.2, 2.6), respectively. Treatment persistence was lower in females than males (P ≤ 0.001). Lack of effectiveness was the predominant reason to stop, irrespective of gender and bDMARD. CONCLUSIONS: Before starting bDMARDs, females had more severe disease than males and a lower percentage reached favourable disease states, with lower persistence of treatment after 12 months. A better understanding of the mechanisms underlying these differences may improve therapeutic management in females with PsA. TRIAL REGISTRATION: ClinicalTrials.gov, https://clinicaltrials.gov, NCT02627768.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Van Kuijk AWR, Nurmohamed MT, Siebert S, et al. Gender-specific differences in patients with psoriatic arthritis receiving ustekinumab or tumour necrosis factor inhibitor: real-world data. Rheumatology (Oxford). 2023. PMID: 36810788. doi:10.1093/rheumatology/kead089

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。